The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer

Expert Opinion on Investigational Drugs
Hideaki MiyakeMartin E Gleave

Abstract

This review summarise the authors' recent experience in the development of antisense (AS) oligodeoxynucleotide (ODN) therapy that targets a cytoprotective gene, clusterin, for the treatment of prostate cancer. The acquisition of resistance to a wide variety of proapototic stimuli was initially demonstrated by introducing the clusterin gene into prostate cancer cells. Furthermore, silencing clusterin expression using AS ODN synergistically enhanced the effects of several conventional therapeutic modalities through the effective induction of apoptosis in prostate cancer xenograft models. Based on these outcomes, Phase I clinical trials were conducted using AS clusterin ODN incorporating 2'-O-(2-methoxy)ethyl-gapmer backbone (OGX-011), and the optimal dose of OGX-011 capable of inducing </= 90% suppression of clusterin in human prostate cancer tissue was determined. Collectively, these findings suggest the utility of inactivating clusterin function using AS ODN technology as a novel therapeutic strategy for prostate cancer treatment. There have been four kinds of Phase II studies that have begun to further evaluate the efficacy of OGX-011 in patients with prostate, breast and lung cancers.

References

Nov 1, 1992·The Journal of Clinical Investigation·L E FrenchJ A Schifferli
Jan 1, 1986·The Prostate·M L MontpetitM Tenniswood
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P DashP Goelet
Jul 1, 1995·The International Journal of Biochemistry & Cell Biology·M E Rosenberg, J Silkensen
Feb 1, 1994·The Journal of Clinical Investigation·L E FrenchJ A Schifferli
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·Z Dominski, R Kole
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·S T Crooke, C F Bennett
Jul 17, 1997·Nature·Q L DeverauxJ C Reed
Sep 1, 1997·The Prostate·D G Tang, A T Porter
Jan 10, 1998·The Biochemical Journal·D MichelG Brun
Mar 6, 1999·The Journal of Biological Chemistry·D T HumphreysM R Wilson
Oct 21, 1999·Journal of the National Cancer Institute·L BubendorfO P Kallioniemi
Apr 20, 2000·The Journal of Biological Chemistry·M CervelleraA Sala
May 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·C R YangD A Boothman
Aug 10, 2000·The American Journal of Pathology·M RedondoC K Petito
Mar 22, 2001·Journal of the National Cancer Institute·O GautschiU Zangemeister-Wittke
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·I Lebedeva, C A Stein
Sep 26, 2001·Neoplasia : an International Journal for Oncology Research·T ZellwegerM E Gleave
Dec 26, 2001·The Journal of Biological Chemistry·Takeshi UedaMarianne D Sadar
Aug 30, 2002·The International Journal of Biochemistry & Cell Biology·Ioannis P Trougakos, Efstathios S Gonos
Nov 30, 2002·Expert Opinion on Investigational Drugs·Janet R Walczak, Michael A Carducci
Jan 29, 2003·The Journal of Biological Chemistry·Konstantin S LeskovDavid A Boothman
Jun 5, 2003·Current Opinion in Oncology·Jonathan Rosenberg, Eric J Small

❮ Previous
Next ❯

Citations

Jun 2, 2011·Cancer Chemotherapy and Pharmacology·Ching-Yuan ChengGwo-Tarng Sheu
Sep 6, 2007·The Journal of Clinical Investigation·Russel S TaichmanKenneth J Pienta
Dec 7, 2007·The Journal of Clinical Investigation·David R Corey
Aug 28, 2015·Expert Review of Anticancer Therapy·Lateef A Muhammad, Fred Saad
Oct 1, 2008·Expert Opinion on Drug Discovery·Ravinder Malik, Ipsita Roy
Sep 1, 2008·Expert Opinion on Drug Discovery·Douglas W Leaman
Apr 25, 2009·International Journal of Cancer. Journal International Du Cancer·Li WeiXiaoyan Xin
Apr 1, 2010·BJU International·Karim FizaziMajid Tabesh
Apr 17, 2013·International Journal of Oncology·Paolo FuzioElda Perlino
Feb 5, 2008·Cancer Research·Wadih ArapRenata Pasqualini
Nov 21, 2007·Molecular Cancer Therapeutics·David A SallmanJulie Y Djeu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.